Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer

被引:145
作者
Truninger, K
Menigatti, M
Luz, J
Russell, A
Haider, R
Gebbers, JO
Bannwart, F
Yurtsever, H
Neuweiler, J
Riehle, HM
Cattaruzza, MS
Heinimann, K
Schär, P
Jiricny, J
Marra, G
机构
[1] Univ Zurich, Inst Mol Canc Res, CH-8008 Zurich, Switzerland
[2] Cantonal Hosp Aarau, Div Gastroenterol, Aarau, Switzerland
[3] Cantonal Hosp Aarau, Inst Pathol, Aarau, Switzerland
[4] Univ Basel, Res Dept, DKBW, Res Grp Human Genet, Basel, Switzerland
[5] Triemli Hosp Zurich, Inst Pathol, Zurich, Switzerland
[6] Cantonal Hosp Lucerne, Inst Pathol, Luzern, Switzerland
[7] Cantonal Hosp St Gallen, Inst Pathol, St Gallen, Switzerland
[8] Univ Zurich Hosp, Inst Pathol, CH-8091 Zurich, Switzerland
[9] Univ Roma La Sapienza, Dept Publ Hlth, Rome, Italy
关键词
D O I
10.1053/j.gastro.2005.01.056
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Germline mutations in the DNA mismatch repair (MMR) genes MSH2, MSH6, or MLH1 predispose to colorectal cancer (CRC) with an autosomal dominant inheritance pattern. The protein encoded by PMS2 is also essential for MMR; however, alterations in this gene have been documented only in extremely rare cases. We addressed this unexpected finding by analyzing a large series of CRCs. Methods: Expression of MSH2, MSH6, MSH1, and PMS2 was studied by immunohistochemistry in 1048 unselected, consecutive CRCs. Where absence of MMR proteins was detected, microsatellite instability and cytosine methylation of the respective gene promoter were analyzed. The DNA of patients presenting with PMS2-deficient cancers was examined for germline and somatic alterations in the PMS2 gene. Results: An aberrant pattern of MMR protein expression was detected in 13.2% of CRCs. Loss of expression of MSH2, MSH6, or MLH1 was found in 1.4%, 0.5%, and 9.8%, respectively. PMS2 deficiency accompanied by microsatellite instability was found in 16 cases (1.5%) with a weak family history of cancer. The PMS2 promoter was not hypermethylated in these cases. Despite interference of the PMS2 pseudogenes, we identified several heterozygous germline mutations in the PMS2 gene. Conclusions: PMS2 defects account for a small but significant proportion of CRCs and for a substantial fraction of tumors with microsatellite instability. However, the penetrance of heterozygous germline mutations in PMS2 is considerably lower than that of mutations in other MMR genes. The possible underlying causes of this unorthodox inheritance pattern are discussed.
引用
收藏
页码:1160 / 1171
页数:12
相关论文
共 53 条
[31]   FOUNDING MUTATIONS AND ALU-MEDIATED RECOMBINATION IN HEREDITARY COLON-CANCER [J].
NYSTROMLAHTI, M ;
KRISTO, P ;
NICOLAIDES, NC ;
CHANG, SY ;
AALTONEN, LA ;
MOISIO, AL ;
JARVINEN, HJ ;
MECKLIN, JP ;
KINZLER, KW ;
VOGELSTEIN, B ;
DELACHAPELLE, A ;
PELTOMAKI, P .
NATURE MEDICINE, 1995, 1 (11) :1203-1206
[32]   PMS2-related genes flank the rearrangement breakpoints associated with Williams syndrome and other diseases on human chromosome 7 [J].
Osborne, LR ;
Herbrick, JA ;
Greavette, T ;
Heng, HHQ ;
Tsui, LC ;
Scherer, SW .
GENOMICS, 1997, 45 (02) :402-406
[33]   Involvement of hMSH6 in the development of hereditary and sporadic colorectal cancer revealed by immunostaining is based on germline mutations, but rarely on somatic inactivation [J].
Plaschke, J ;
Krüger, S ;
Pistorius, S ;
Theissig, F ;
Saeger, HD ;
Schackert, HK .
INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (05) :643-648
[34]   Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair [J].
Prolla, TA ;
Baker, SM ;
Harris, AC ;
Tsao, EL ;
Yao, X ;
Bronner, CE ;
Zheng, BH ;
Gordon, M ;
Reneker, J ;
Arnheim, N ;
Shibata, D ;
Bradley, A ;
Liskay, RM .
NATURE GENETICS, 1998, 18 (03) :276-279
[35]   Identification of hMutLβ, a heterodimer of hMLH1 and hPMS1 [J].
Räschle, M ;
Marra, G ;
Nyström-Lahti, M ;
Schär, P ;
Jiricny, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (45) :32368-32375
[36]   Altered expression of MLH1, MSH2, and MSH6 in predisposition to hereditary nonpolyposis colorectal cancer [J].
Renkonen, E ;
Zhang, YG ;
Lohi, H ;
Salovaara, R ;
Abdel-Rahman, WM ;
Nilbert, M ;
Aittomäki, K ;
Järvinen, HJ ;
Mecklin, JP ;
Lindblom, A ;
Peltomäki, P .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (19) :3629-3637
[37]   Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer [J].
Ribic, CM ;
Sargent, DJ ;
Moore, MJ ;
Thibodeau, SN ;
French, AJ ;
Goldberg, RM ;
Hamilton, SR ;
Laurent-Puig, P ;
Gryfe, R ;
Shepherd, LE ;
Tu, D ;
Redston, M ;
Gallinger, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (03) :247-257
[38]  
Ricciardone MD, 1999, CANCER RES, V59, P290
[39]  
Rigau V, 2003, ARCH PATHOL LAB MED, V127, P694
[40]  
Risinger JI, 1998, CANCER RES, V58, P2978